<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271860/" ref="ordinalpos=139&amp;ncbi_uid=4658859&amp;link_uid=PMC3271860" image-link="/pmc/articles/PMC3271860/figure/F7/" class="imagepopup">Figure 7. CDDP-R cells have greater IGF <span class="highlight" style="background-color:">pathway</span> activation than the parental H460 cell line.  From: THE ROLE OF IGF-1 <span class="highlight" style="background-color:">SIGNALING</span> <span class="highlight" style="background-color:">PATHWAY</span> IN CISPLATIN-RESISTANT LUNG CANCER CELLS. </a></div><br /><div class="p4l_captionBody">Binding of IGFBP-3 to IGF-1 prevents receptor binding and downstream pathway activation. With decreased expression of IGFBP-3 in CDDP-R cells, IGF-1 signaling through IGF-1R is maximized, leading to increased metabolism, proliferation, and survival through the Ras-raf-MAPK and PI3K-PDK/AKT-TOR-S6K pathways.</div></div>